We are live on ! Find out more
GANX icon

Gain Therapeutics

42 hedge funds and large institutions have $15.8M invested in Gain Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

402% more call options, than puts

Call options by funds: $502K | Put options by funds: $100K

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

4% less capital inflows, than outflows

Capital inflows: $1.86M | Capital outflows: $1.94M

1.55% less ownership

Funds ownership: 20.95% → 19.4% (-1.6%)

13% less funds holding

Funds holding: 48 → 42 (-6)

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

Holders
42
Holders Change
-6
Holders Change %
-12.5%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
9
Reduced
9
Closed
16
Calls
$502​K
Puts
$100​K
Net Calls
+$402​K
Net Calls Change
+$173​K

GANX Hedge Fund Activity: Q1 2026 in Review

42 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2026, worth a combined $15.8M — down 39% from $25.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GANX and 7 opened new positions — a net loss of 9 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was GSA Capital Partners, adding an estimated $635K. The largest seller was Susquehanna International Group, cutting an estimated $551K.

  • 42 institutional investors held Gain Therapeutics (GANX) as of Q1 2026, down from 48 in Q4 2025.
  • Funds reported $15.8M of Gain Therapeutics stock for Q1 2026, down 39% quarter-over-quarter.
  • 7 funds opened new Gain Therapeutics positions in Q1 2026 and 16 closed out, a net change of -9 holders.
  • The largest Gain Therapeutics buyer in Q1 2026 was GSA Capital Partners, an estimated $635K added.
  • The largest Gain Therapeutics seller in Q1 2026 was Susquehanna International Group, an estimated $551K sold.

Based on aggregated 13F filings for Q1 2026.